Research
Evidence, read off the primary source — page 4
No pattern-matched citations and no PMIDs pulled from memory. Every regulatory date, study, and label quote below was fetched live and checked against its primary source before publication — see each article's reference list. 82 articles published so far.
How we verify a source
A PubMed citation is checked against PubMed's own record, not typed from recall. A regulatory page is fetched live and quoted, not paraphrased from a secondary blog. If a claim cannot be verified this way, it is softened or removed — never guessed.
Filter by topic
Showing 73–82 of 82 articles
Evidence review
Tesamorelin Dosing: What the Egrifta FDA Label Actually Specifies
Tesamorelin's dose is on a real FDA label — 1.4 mg (Egrifta SV) or 1.28 mg (Egrifta WR), daily, for a specific HIV indication. Here's exactly what it says.
ReadEvidence review
Tesamorelin Side Effects: What Egrifta's Own FDA Label Reports
Tesamorelin has a current FDA label, unlike sermorelin. Here's what it warns about — neoplasms, IGF-1, glucose intolerance, and a real statistical tension.
ReadEvidence review
Tirzepatide Dosage Chart: The Titration Ladder the FDA Label Actually Specifies
The tirzepatide dosage chart, read off the Zepbound and Mounjaro labels: the 2.5 to 15 mg ladder, escalation timing, missed doses, and the mg/mL conversion.
ReadEvidence review
Tirzepatide Side Effects: What Its FDA Label and Pivotal Trials Actually Report
Tirzepatide has an FDA label with a boxed warning and real per-dose trial data. Here's what Zepbound, Mounjaro, and their pivotal trials actually reported.
ReadEvidence review
Vyleesi (PT-141) for Women's Libido and HSDD: What the Label and Trials Actually Show
Vyleesi (bremelanotide) is FDA-approved for premenopausal HSDD. Here's what the RECONNECT trials and its own label say — and why this site has no board for it.
ReadEvidence review
What Is Compounded Tirzepatide? What Compounding Means, How It Differs From Zepbound, and What to Check
Compounded tirzepatide is not a generic and not FDA-approved. What compounding legally is, how a compounded vial differs from Zepbound, and what to check.
ReadEvidence review
Retatrutide Dosing: The Doses and Titration Schedules Actually Tested in Its Clinical Trials
Retatrutide has no FDA-approved dose. Here is the titration schedule and dose arms its own phase 2 and phase 3 trials actually used — not dosing advice.
ReadEvidence review
Retatrutide Side Effects: What Its Clinical Trials Have Actually Reported
Retatrutide has no FDA label, so there's no official side-effect list. Here's the adverse-event data its own published and topline trials reported.
ReadEvidence review
Retatrutide: What's Actually Approved, What's Actually Known, and What It Actually Costs Right Now
Retatrutide has no FDA approval and no legal purchase pathway — what "buy retatrutide" searches actually find, and what's available today.
ReadEvidence review
Tirzepatide, Birth Control, and PCOS Fertility: What the Evidence Actually Shows
Tirzepatide's FDA label warns oral birth control may not work as well; semaglutide's does not. GLP-1s can also restore ovulation in PCOS. Here is the evidence.
Read
Nothing matches these filters
No article matches both the search text and the topic selected. Try clearing one of the two filters.